LCLAT1 and Parkinson disease: Overexpression of LCLAT1 and subsequent CL remodeling, as observed in our ETMR samples and preclinical model, have been proposed to reflect pathogenic changes that drive multiple metabolic and aging-related diseases, including obesity, type 2 diabetes, Parkinson’s disease, cardiomyopathies, and cancer.30